围手术期FOLFOX 4对比FOLFOX 4联合西妥昔单抗对比立即手术用于高危II期和III期结肠癌:II期多中心随机对照试验(PRODIGE 22)
这项法国多中心随机II期试验纳入可切除的高危T3、T4和/或N2结肠癌患者,比较术后辅助FOLFOX与围手术期FOLFOX(术前4周期+术后8周期),RAS野生型患者另设围手术期FOLFOX联合西妥昔单抗组。主要终点为Ryan肿瘤消退分级(TRG1)。围手术期FOLFOX未提高主要病理缓解率(TRG1=8%),但显著增加病理消退(TRG1-2=44% vs 8%,P<0.001)并有降期趋势,耐受性可接受。
要点
- 围手术期FOLFOX未提高主要病理缓解率(TRG1=8%)。
- 围手术期FOLFOX显著增加病理消退(TRG1-2=44% vs 8%,P<0.001)并有降期趋势。
- 围手术期FOLFOX可行且耐受性可接受,R0切除率94%,完整结肠系膜切除率93%。
核心结论
- 围手术期FOLFOX用于局部晚期可切除结肠癌可行且耐受性可接受,但未如预期提高主要病理缓解率。
- 围手术期FOLFOX诱导病理消退和降期。
- 需要更好的术前分期工具以降低过度治疗风险。
研究设计与样本
- 法国多中心随机II期试验,纳入基线CT可切除的高危T3、T4和/或N2结肠癌患者。
- 随机分为术后辅助FOLFOX 6个月(对照组)或围手术期FOLFOX(术前4周期+术后8周期)。
- RAS野生型患者增加围手术期FOLFOX联合西妥昔单抗组。
- 主要终点为Ryan等人提出的肿瘤消退分级(TRG1)。
- 共入组120例;中期分析时FOLFOX联合西妥昔单抗组因缺乏疗效停止;意向治疗人群104例(对照组52例,围手术期FOLFOX组52例)。
主要发现
- 围手术期FOLFOX组96%患者完成术前计划的4周期化疗。
- R0切除率为94%,完整结肠系膜切除率为93%。
- 两组总死亡率和并发症发生率相似。
- 围手术期FOLFOX未提高主要病理缓解率(TRG1=8%)。
- 围手术期FOLFOX显著增加病理消退(TRG1-2=44% vs 8%,P<0.001),并有降期趋势。
关键数值与推荐
- 主要病理缓解定义为TRG1。
- 围手术期FOLFOX组TRG1率为8%,与对照组相比未提高。
- TRG1-2率围手术期FOLFOX组为44%,对照组为8%(P<0.001)。
临床怎么用
- 围手术期FOLFOX可作为局部晚期可切除结肠癌的一种可行治疗选择,耐受性可接受。
- 围手术期FOLFOX可诱导病理消退和降期,但未提高主要病理缓解率。
- 应使用更好的术前分期工具以减少过度治疗。
局限性
- II期试验,样本量有限(意向治疗人群104例)。
- FOLFOX联合西妥昔单抗组因缺乏疗效提前终止。
- 对照组CT分期存在33%的过度分期率,可能影响分期准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perioperative chemotherapy has proven valuable in several tumors, but not in colon cancer (CC). OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of perioperative chemotherapy in patients with locally advanced nonmetastatic CC. METHODS: This is a French multicenter randomized phase II trial in patients with resectable high-risk T3, T4, and/or N2 CC on baseline computed tomography (CT) scan. Patients were randomized to receive either 6 months of adjuvant FOLFOX after colectomy (control) or perioperative FOLFOX for 4 cycles before surgery and 8 cycles after (FOLFOX peri-op). In RAS wild-type patients, a third arm testing perioperative FOLFOX-cetuximab was added. Tumor Regression Grade (TRG1) of Ryan et al was the primary endpoint. Secondary endpoints were toxicity, perioperative morbidity, and quality of surgery. RESULTS: A total of 120 patients were enrolled. At interim analysis, the FOLFOX-cetuximab arm was stopped (lack of efficacy). The remaining 104 patients (control, n = 52; FOLFOX preop n = 52) represented our intention-to-treat population. In the FOLFOX perioperative group, 96% received the scheduled 4 cycles before surgery. R0 resection and complete mesocolic excision rate were 94% and 93%, respectively. Overall mortality and morbidity rates were similar in both groups. Perioperative FOLFOX chemotherapy did not improve major pathological response rate (TRG1 = 8%) but was associated with a significant pathological regression (TRG1-2 = 44% vs 8%, P < 0.001) and a trend to tumor downstaging as compared to the control group. CT scan criteria were associated with a 33% rate of overstaging in control group. CONCLUSIONS: Perioperative FOLFOX for locally advanced resectable CC is feasible with an acceptable tolerability but is not associated with an increased major pathological response rate as expected. However, perioperative FOLFOX induces pathological regression and downstaging. Better preoperative staging tools are needed to decrease the risk of overtreating patients.
引用
- Karoui M, Rullier A, Piessen G, et al. Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22). Ann Surg. 2020. PMID: 31356278. doi:10.1097/SLA.0000000000003454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。